<DOC>
	<DOCNO>NCT01928407</DOCNO>
	<brief_summary>A phase IV , prospective , multicenter , randomize open label , 48 week study evaluate antiretroviral efficacy safety atazanavir/ritonavir darunavir/ritonavir , combination fix dose tenofovir disoproxil fumarate- emtricitabine HIV-1-infected treatment-naïve subject CD4 count 200 µL .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Between Two Antiretroviral Regimens , HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts</brief_title>
	<detailed_description>Principal objective To evaluate virological efficacy safety week 48 2 regimen atazanavir/ritonavir ( ATZ/r ) 300/100 mg darunavir/ritonavir ( DRV/r ) 800/100 mg , combination fixed-dose tenofovir/emtracitabine HIV-1 treatment-naïve subject CD4 count 200 µL . Secondary objective - Proportion subjets virologic efficacy week 24 - Proportion subject confirm virologic failure week 24 later - Proportion patient virologic mutation - Evaluate virologic effect seminal fluid - To evaluate immunological response time week 48 - To assess plasma seminal pharmacokinetics drug treatment regimen week 4 , 24 , 48 - Correlate pharmacokinetic property drug virologic outcome plasma semen week 4 48 - Correlate free fraction ( bound protein ) atazanavir darunavir plasma semen virologic outcome - Evaluate relationship bilirubinemia atazanavir - Change baseline fasting lipid , fast glucose insulin time 2 arm - Compare adherence patient satisfaction sexual behaviour regimens Methodology This 48 week , multicentre , prospective , open label , phase IV , randomize . non comparative , study . Inclusion criterion - Male female , age &gt; 18 year age . - HIV-1 infection determine positive ELISA confirm Western blot - Plasma HIV-RNA &gt; 1 000 c/mL - CD4+T cell count &lt; =200 cells/mm3 time screening , &lt; =250 cells/mm3 CD4 count &lt; 200 cells/mm3 12 week screen . - Women childbearing potential must agree use effective method barrier contraception document sterility . - Subjects must medical insurance throught Securite Sociale - Ability understand provide write informed consent . Non-inclusion criterion - Acute opportunistic infection within past two week - HIV-2 infection - pregnant woman - Any subject drug resistance mutation screen - Any subject grade 3 great clinical laboratory adverse event screen - Any subject received antiretoviral therapy except prevention mother child transmission patient receive post exposure prophylaxis month less - calculated creatinine clearance &lt; 60/mL estimate Cockcroft- Gault equation - Patients opinion investigator unlikley able follow study instruction - Any subject unable take antiretroviral medication whatever reason - Any subject taking treatment medication contraindicate co-administered arm drug treatment . Treatment : - Group 1 : ATV + TDF/FTC ( Abacavir/Lamivudine , [ ABC/3TC ] , TDF/FTc contre-indicated - atazanavir/ritonavir 300/100mg/day TDF/FTC 245 /200 mg day , 3 pill day , 48 week meal - Group 2 : DRV+ TDF/FTC ( ABC/3TC TDF/FTc contre-indicated ) - darunavir/ritonavir 800/100mg/day TDF/FTC 245 /200 mg day , 4 pill day , 48 week meal Primary Endpoints : - Proportion patient HIV-1 plasma viral load 50 copies/mL week 48 receive initial regimen - Proportion patient experience grade 2-4 adverse clinical laboratory event include hematology , chemistry , lipid ( total cholesterol , HDL cholesterol , LDL cholesterol , triglyceride ) , glucose insulin week 48 . Secondary endpoint : - Proportion patient plasma HIV RNA 50 cp/mL week 24 - Proportion patient HIV RNA &gt; 50 cp/mL week 24 later confirm second HIV RNA least 14 day first test - Development resistance mutation subject virologic failure test 24 week later test genotypic resistance test - Evaluate virologic effect seminal fluid baseline , W4 W48 change HIV RNA concentration semen time - To evaluate immunological response time week 48 2 arm CD4 cell count ( W-4 , W2 , W4 , W12 , W36 W48 ) , differenciation activation T CD4 ( W2 , W4 , W12 , W24 W48 ) ; Change lymphocyte subset reconsistution week 48 compare baseline . ; Change immunolgic marker inflammation week 2 , 4 , 12 , 24 , 48 - To assess plasma seminal pharmacokinetics drug treatment regimen week 4 , 24 , 48 residual concentration ( C min ) antiretroviral drug W4 , W24 , W48 - Atazanavir darunavir ( plasma seminal ) drug concentration coorelation adverse clinical laboratory event . - Evaluate relationship bilirubinemia atazanavir pharmacokinetics ( Cmin ) - Evolution lipid , glucose insulin parameter baseline week 24 48 - Adherence regimen , patient satisfaction sexual behaviour regimen W2 , W24 W48 mesured ( mettre ref ) - Evolution anthropomorphic measurement baseline week 24 , 48 . Substudies Brief description ( 2 line maximum ) person charge substudy - Immunologic substudy ( Pr Brigitte Autran ) : Change immunolgic marker inflammation week 2 , 4 , 12 , 24 , 48 change lymphocyte subset reconsistution week 48 compare baseline . - Pharmacologic substudy ( Dr Gilles Peytavin ) : To assess plasma seminal pharmacokinetics drug treatment regimen week 4 , 24 , 48 residual concentration ( C min ) antiretroviral drug W4 , W24 , W48 - Virologic substudy ( Dr Anne Geneviève Marcelin ) : Evaluate virologic effect seminal fluid baseline , W4 W48 - Behaviour substudy ( Dr France Lert ) : Compare adherence patient satisfaction sexual behaviour regimen W2 , W24 W48 Estimated enrolment : 120 subject ( 60 per group ) randomly assign 1:1</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Inclusion Criteria Male female , age &gt; 18 year age HIV1 infection determine positive ELISA confirm Western blot Plasma HIVRNA &gt; 1 000 c/mL CD4+T cell count &lt; =200 cells/mm3 time screening , &lt; =250 cells/mm3 CD4 count &lt; 200 cells/mm3 12 week screen Women childbearing potential must agree use effective method barrier contraception document sterility Subjects must medical insurance throught Securite Sociale Ability understand provide write informed consent Exclusion Criteria Acute opportunistic infection within past two week HIV2 infection Pregnant woman Any subject drug resistance mutation screen Any subject grade 3 great clinical laboratory adverse event screen Any subject receive antiretoviral therapy except prevention mother child transmission patient receive post exposure prophylaxis month less Calculated creatinine clearance &lt; 60/mL estimate Cockcroft Gault equation Patients opinion investigator unlikley able follow study instruction Any subject unable take antiretroviral medication whatever reason Any subject take treatment medication contraindicate coadministered arm drug treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>naif , CD4 &lt; 200 cell/mm3 , Atazanavir , Darunavir</keyword>
</DOC>